Abstract:Abstract Background: Prior infection with Chlamydia trachomatis, indicated by the presence of circulating antibodies against plasmid encoded glycoprotein 3 (Pgp3), is associated with an increased risk of ovarian cancer. The aberrant expression of p53 can be found in up to 95% of ovarian cancers and is an especially frequent feature among high-grade serous cancers. Prior studies have described mechanisms by which Chlamydia reprogram DNA damage response pathways, including those involving p53. However, tumor level expression of p53 among women with and without prior exposure to chlamydia is poorly described. We evaluated whether the association between prior chlamydial infection (Pgp3 seropositivity) and ovarian cancer varied by tumor p53 expression and whether Pgp3 seropositivity was associated with ovarian tumor expression of p53. Methods: Available serologic data for Pgp3 in tubo-ovarian cancer cases (n=155) and matched controls (n=556) from the Polish Ovarian Cancer Study were evaluated and stratified by p53 mutation status of cases inferred from immunohistochemical staining. Expression of p53 was assessed in tissue microarrays (2+ cores per case) and classified as aberrant (i.e., no expression or overexpression: ≥60% positive cells) or wild- type. Multinomial logistic regression with controls as the reference was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association of Pgp3 seropositivity with ovarian cancer with stratification by p53 expression among the cases. Logistic regression among cases was only used to evaluate the association between Pgp3 and aberrant p53 expression. Results: Aberrant p53 expression was found in 70% of cases. Pgp3 seropositivity was associated with increased ovarian cancer risk (OR [95% CI]: 1.86 [1.28-2.68]). Pgp3 seropositivity was associated with risk for both p53 aberrant (1.79 [1.16-2.75]) or p53 wild-type ovarian cancers (2.06 [1.11-3.80], p for heterogeneity=0.80). When restricted to high-grade serous cancers, the association with Pgp3 was also not differential by p53 status (p for heterogeneity=0.16; 83% of high-grade serous cases had aberrant p53 expression). Among women with cancer, Pgp3 seropositivity was not associated with aberrant p53 expression (versus wild-type, OR [95% CI]: 0.90 [0.45-1.81], spearman correlation: -0.05, p-value=0.55). Conclusion/Discussion: Our study provides support that previous C. trachomatis infection is associated with ovarian cancer, irrespective of aberrant p53 tumor expression. There are many possible mechanisms by which Chlamydia may influence ovarian cancer. While the current results do not rule out interactions with p53-related pathways, it is likely that C. trachomatis increases ovarian cancer risk via multiple mechanisms (e.g., infection related sequelae like chronic inflammation). Citation Format: Sarina Pollat, Nicolas Wentzensen, Tim Waterboer, Manila Hada, Jolanta Lissowska, Beata Peplonska, Mark E. Sherman, Kara A. Michels, Britton Trabert. Prior chlamydial infection and ovarian cancer risk by tumor p53 expression [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr A051.

Association of Chlamydia Trachomatis Infection with Breast Cancer Risk and the Modification Effect of IL-12

PPRs and Gene Polymorphisms and Chlamydia Trachomatis-associated Tubal Factor Infertility

Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations

Genetic Susceptibility Loci for Chlamydia Trachomatis Endometrial Infection Influence Expression of Genes Involved in T Cell Function, Tryptophan Metabolism and Epithelial Integrity.

The study of the effect of chlamydia trachomatis on the immunological responses of female genital tract epithelium

Interactions Between Vaginal Local Cytokine IL-2 and High-Risk Human Papillomavirus Infection with Cervical Intraepithelial Neoplasia in a Chinese Population-Based Study

Associations of Chlamydia trachomatis serology with fertility-related and pregnancy adverse outcomes in women: a systematic review and meta-analysis of observational studies

Abstract A051: Prior chlamydial infection and ovarian cancer risk by tumor p53 expression

Chlamydia Trachomatis Infection: Their potential implication in the Etiology of Cervical Cancer

Interactions of IL-12A and IL-12B Polymorphisms on the Risk of Cervical Cancer in Chinese Women

Interleukin-12B Rs3212227 Polymorphism and Cancer Risk: a Meta-Analysis.

Predictive Role of Serum Cholesterol and Triglycerides in Cervical Cancer Survival.

Host Genetic Risk Factors for Chlamydia Trachomatis-Related Infertility in Women.

57: EVALUATION OF THE CIRCULATING LEVELS OF IL-12 AND IL-33 IN PATIENTS WITH BREAST CANCER: INFLUENCES OF THE TUMOR STAGES AND CYTOKINE GENE POLYMORPHISMS

Association Analysis of Interleukin-18 Gene Promoter Region Polymorphisms and Susceptibility to Sporadic Breast Cancer in Chinese Han Women.

Stratification Analysis and Case-Control Study of Relationships Between Interleukin-6 Gene Polymorphisms and Cervical Cancer Risk in a Chinese Population.

Distribution of Chlamydia trachomatis ompA genotypes and its association with abnormal cervical cytology among women of reproductive age in Shenzhen, China

Appraisal of the causal effect of Chlamydia trachomatis infection on epithelial ovarian cancer risk: a two-sample Mendelian randomisation study

Interleukin-10 Gene Polymorphisms Modulate the Risk of Infertility in Chlamydia trachomatis Positive Kurdish Women in Erbil Province

Association between co-infection with Chlamydia trachomatis or Mycoplasma genitalium and cervical lesions in HPV-positive population in Hunan, China: a cross-sectional study

Trichomonas Vaginalis Infection-Associated Risk of Cervical Cancer: A Meta-Analysis.